PB2172: IRON OXIDE NANOPARTICLES INHIBIT DIFFUSE LARGE B LYMPHOMA CELL SURVIVAL AND INVASION

Abstract

Background: Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma world wide. It is a phenotypically and genetically heterogeneous disease, accounting for 30-40% of all cases. 50%-70% of patients can be cured by the R-CHOP regimen, but nearly one-third of patients develop relapsed or refractory disease. Until now, the Food and Drug Administration (FDA)-approved iron supplement ferumoxytol and other iron oxide nanoparticles have been used for treating iron deficiency, as contrast agents for magnetic resonance imaging and as drug carriers. But recently, more studies have revealed a hidden intrinsic therapeutic effect of ferumoxytol on tumors, but the role and mechanism in DLBCL has not been reported yet. Aims: The purpose of this study is to investigate the effect of iron oxide nanoparticles on DLBCL cells proliferation and migration by in vitro and in vivo. Methods: Different concentrations of iron oxide nanoparticles were applied to DLBCL cell lines, such as SUDHL-2 and SUDHL-4 cells, and control cells were treated with equal amounts of PBS. The proliferation, migration, apoptosis and reactive oxygen (ROS) were detected by CCK8, transwell, flow cytometry (FC) and Multifunctional Fluorescence Enzyme Marker, respectively in vitro. The engraftment, tumor growth, dissemination and survival time were observed in BALB/c nude mice and NOD-SCID mice. Results: Iron oxide nanoparticles inhibited DLBCL cells proliferation, migration and anti-apoptosis ability. The mechanism involved in the proliferation and migration of DLBCL cells by promoting the production of ROS. Furthermore, administration of iron oxide nanoparticles decreased tumor growth and dissemination of DLBCL cells, and increased survival time in the xenograft model. Summary/Conclusion: Our study demonstrates that iron oxide nanoparticles cound inhibit DLBCL cells proliferation, migration, and promote apoptosis. The supplement of iron may, therefore, be a potential target for anticancer therapy in DLBCL.